Have GlaxoSmithKline plc, Diageo plc and WM Morrison plc finally turned the corner?

GlaxoSmithKline plc (LON: GSK), Diageo plc (LON: DGE) and WM Morrison plc (LON: MRW) have backed themselves out of a corner and are ready to hit the road, says Harvey Jones

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When big companies lose their way, it can take them a long time to get on track. The following three stocks have rattled off in the wrong direction in recent years, can they find their way back?

Brightening outlook

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) is seen as one of the safest bets on the FTSE 100 but it has hasn’t been a winning one in recent years. The stock is up just 7.5% over the past five years, although in fairness, that is double the growth on the FTSE 100. The reasons Glaxo went AWOL have been well documented, including the embarrassing China bribery scandal, and far more damaging concerns about prospects for its drug pipeline.

The outlook is finally brightening on the latter front with first quarter results showing new product sales soaring to £821m, more than double the same period last year. New pharmaceutical product sales now represent 20% of total pharma sales, driven by HIV, respiratory and meningitis vaccines. Sales from this source offset about 70% of the decline in former cash cow Seretide/Advair.

The results suggest to me that Glaxo is turning the corner, with first quarter sales up 11% to £6.2bn and core earnings per share up 14% to 19.8p. Management’s plan to diversify from blockbuster treatments into consumer health vaccines should also keep things moving along. The yield still looks lovely at 5.52%, the only downside being that Glaxo is no longer cheap, trading at 19.15 times earnings.

Lacklustre performance

It is a long time since global drinks giant Diageo (LSE: DGE) showed some spirit. Its has struggled since new boss Ivan Menezes took over the reigns from acquisition-thirsty predecessor Paul Walsh three years ago. Lacklustre performance has forced Menezes to water down his own earnings, slashing his pay from £7.3m to £3.9m last year. His “Drink Better” campaign equated to “Drink Less” in practice.

Menezes cannot be blamed for the emerging market slowdown, or the Chinese crackdown on gift giving, but it is hard for him to shrug off the sales slowdown in North America. Diageo’s share price has been in slow decline for three years yet Diageo nevertheless trades at a surprisingly pricey 21.27 times earnings. However, a solid 3.07% yield and forecast EPS growth of 9% in the year to June 2017 (after three years of declines) may also tempt optimists.

No mean feat

WM Morrison (LSE: MRW) endured such a dramatic fall from grace that it was hard to see a way back for the struggling grocery chain. Yet sentiment turned and today’s price of 190p is comfortably above its 52-week low of 139p.

The German discounters will continue to nibble at its heels but chief executive David Potts recently delivered like-for-like sales growth of 0.7% in the 13 weeks to May, no mean feat in this environment, and Morrisons continues to generate plenty of cash. Plans to simultaneously improve the customer experience and drive down net debt target appear to be paying off.

This is a tough sector, but Morrisons looks like it might just tough things out. It may trade at a pricey 24.5 times earnings but forecast EPS growth of 31% suggest this could just be justified.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »